Morgan Stanley
ENFN

Morgan Stanley’s Enfusion, Inc. ENFN Stock Holding History

Morgan Stanley’s Portfolio ENFN Stock Details ENFN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-282,306
Closed -$3.15M – 8352
2025
Q1 		$3.15M Sell
282,306
-238,693
-46% -$2.64M ﹤0.01% 4294
2024
Q4 		$5.37M Buy
520,999
+89,681
+21% +$867K ﹤0.01% 3927
2024
Q3 		$4.09M Buy
431,318
+141,039
+49% +$1.22M ﹤0.01% 4118
2024
Q2 		$2.47M Buy
290,279
+166,585
+135% +$1.52M ﹤0.01% 4413
2024
Q1 		$1.14M Sell
123,694
-249,990
-67% -$2.2M ﹤0.01% 4886
2023
Q4 		$3.62M Buy
373,684
+200,088
+115% +$1.87M ﹤0.01% 4575
2023
Q3 		$1.56M Buy
173,596
+47,730
+38% +$453K ﹤0.01% 4543
2023
Q2 		$1.41M Buy
125,866
+15,752
+14% +$140K ﹤0.01% 4621
2023
Q1 		$1.16M Buy
110,114
+95,077
+632% +$1.05M ﹤0.01% 4772
2022
Q4 		$145K Sell
15,037
-13,216
-47% -$149K ﹤0.01% 5800
2022
Q3 		$348K Sell
28,253
-10,905
-28% -$133K ﹤0.01% 5453
2022
Q2 		$400K Buy
39,158
+35,692
+1,030% +$394K ﹤0.01% 5531
2022
Q1 		$43K Buy
3,466
+870
+34% +$13.3K ﹤0.01% 6783
2021
Q4 		$55K Buy
+2,596
New +$52.5K ﹤0.01% 6771

Other funds holding ENFN

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Morgan Stanley's ENFN Position: Q2 2025 in Review

Morgan Stanley sold out of Enfusion, Inc. (ENFN) in Q2 2025, closing a stake of 282,306 shares — an estimated $3.15M sold.

Morgan Stanley first reported a position in ENFN in Q4 2021 and held it in 14 quarters. The position peaked at $5.37M in Q4 2024. 2 funds tracked by Wall St. Rank hold ENFN as of Q2 2025.

  • Morgan Stanley reported no remaining Enfusion, Inc. position as of Q2 2025 after selling out during the quarter.
  • Morgan Stanley sold 282,306 Enfusion, Inc. shares in Q2 2025, an estimated $3.15M.
  • Morgan Stanley first reported a position in Enfusion, Inc. in Q4 2021 and held it in 14 quarters.
  • Morgan Stanley's Enfusion, Inc. position peaked at $5.37M in Q4 2024.
  • 2 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.